184 related articles for article (PubMed ID: 35576176)
1. Current Treatment of Peripheral T-cell Lymphoma.
Stuver R; Epstein-Peterson ZD; Johnson WT; Khan N; Lewis N; Moskowitz AJ; Sauter CS; Horwitz S
Oncology (Williston Park); 2022 May; 36(5):293-305. PubMed ID: 35576176
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
Rogers AM; Brammer JE
Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
[TBL] [Abstract][Full Text] [Related]
3. Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin.
Nizamuddin I; Galvez C; Pro B
Semin Hematol; 2021 Apr; 58(2):85-94. PubMed ID: 33906726
[TBL] [Abstract][Full Text] [Related]
4. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.
Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
Crit Rev Oncol Hematol; 2016 Mar; 99():214-27. PubMed ID: 26811013
[TBL] [Abstract][Full Text] [Related]
5. Frontline Management of Nodal Peripheral T-Cell Lymphomas.
Ngu HS; Savage KJ
Am Soc Clin Oncol Educ Book; 2023 May; 43():e390334. PubMed ID: 37262395
[TBL] [Abstract][Full Text] [Related]
6. Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?
Lunning MA; Horwitz S
Curr Treat Options Oncol; 2013 Jun; 14(2):212-23. PubMed ID: 23568456
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Peripheral T-Cell Lymphoma: Many Shades of Gray.
Lunning MA
Oncology (Williston Park); 2015 Aug; 29(8):545-50. PubMed ID: 26281838
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada.
Zou D; Lee J; Kansal A; Ma W; Harris M; Lisano J; Fenton K; Yu KS
J Med Econ; 2022; 25(1):324-333. PubMed ID: 35172685
[TBL] [Abstract][Full Text] [Related]
9. Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation.
Prochazka V; Faber E; Raida L; Vondrakova J; Kucerova L; Jarosova M; Indrak K; Papajik T
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):63-6. PubMed ID: 19365529
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapeutic advancements in peripheral T-cell lymphoma.
Reddy NM; Evens AM
Semin Hematol; 2014 Jan; 51(1):17-24. PubMed ID: 24468312
[TBL] [Abstract][Full Text] [Related]
11. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Shustov AR;
Cancer; 2019 May; 125(9):1507-1517. PubMed ID: 30694529
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
Shea L; Mehta-Shah N
Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
[TBL] [Abstract][Full Text] [Related]
13. Management of Peripheral T-cell Lymphomas and the Role of Transplant.
Foley NC; Mehta-Shah N
Curr Oncol Rep; 2022 Nov; 24(11):1489-1499. PubMed ID: 35947286
[TBL] [Abstract][Full Text] [Related]
14. FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.
Richardson NC; Kasamon YL; Chen H; de Claro RA; Ye J; Blumenthal GM; Farrell AT; Pazdur R
Oncologist; 2019 May; 24(5):e180-e187. PubMed ID: 30914464
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation.
Prochazka V; Faber E; Raida L; Papajik T; Vondrakova J; Rusinakova Z; Kucerova L; Myslivecek M; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Mar; 155(1):63-9. PubMed ID: 21475380
[TBL] [Abstract][Full Text] [Related]
16. [Current treatment strategies for peripheral T-cell lymphoma].
Munakata W
Rinsho Ketsueki; 2021; 62(8):1112-1120. PubMed ID: 34497198
[TBL] [Abstract][Full Text] [Related]
17. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
Shustov A
Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin in the treatment of CD30+ PTCL.
Barta SK; Gong JZ; Porcu P
Blood; 2019 Dec; 134(26):2339-2345. PubMed ID: 31697814
[TBL] [Abstract][Full Text] [Related]
19. The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study.
Feng X; Guo W; Wang Y; Li J; Zhao Y; Qu L; Yan X; Li J; Guo Q; Young KH; Bai O
Adv Ther; 2022 Jan; 39(1):532-543. PubMed ID: 34797505
[TBL] [Abstract][Full Text] [Related]
20. Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment.
Merdin A; İskender D; Ulu BU; Doğan M; Çakar MK; Dal MS; Altuntaş F
Medicine (Baltimore); 2019 Jul; 98(30):e16482. PubMed ID: 31348254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
